James Creedy's questions to Novo Nordisk A/S (NVO) leadership • Q1 2024
Question
James Creedy asked about the clinical view on desirable fat-to-muscle loss ratios during weight loss and whether data from the SELECT trial indicated any changes in lean body mass composition over time.
Answer
Martin Lange, Head of R&D, explained that physicians generally consider the observed lean mass loss (35-40%) to be within a normal and healthy range for significant weight loss. He cited the positive all-cause mortality data from SELECT as evidence of a healthy weight loss profile and stated he had no specific body composition data from the trial to share.